Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.39 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.38 |
| ▸ | JAK3 | P52333 | 3/20 | 0.37 |
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | TYK2 | P29597 | 2/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | VNN1 | O95497 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584456 | 0.82 | MEN1 (0.37) | P4HTM | |
| SCHEMBL3588187 | 0.81 | AURKA (0.54) | P4HTM | |
| SCHEMBL3575559 | 0.77 | MEN1 (0.53) | — | |
| SCHEMBL3584455 | 0.77 | CSNK2A2 (0.35) | CHEK2JAK1TYK2 | |
| SCHEMBL13314770 | 0.77 | NPC1 (0.54) | — | |
| SCHEMBL29686531 | 0.76 | NNMT (0.58) | NNMTHCAR3JAK3JAK2JAK1 | |
| SCHEMBL29074720 | 0.73 | CHEK2 (0.55) | CHEK2IRAK4PARP10 | |
| SCHEMBL3142614 | 0.73 | NNMT (0.46) | NNMTCHEK2HCAR3P4HTM | |
| SCHEMBL28637666 | 0.72 | GRM5 (0.44) | CHEK2P4HTM | |
| SCHEMBL29686690 | 0.72 | NNMT (0.60) | NNMTHCAR3TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160324-A1 | PYRAZOLE DERIVATIVES AS THAT MODULATE THE ACTIVITY OF CDK, GSK AND AURORA KINASES | CDK1, CDK3, CDK13 | NNMT 639/4885CHEK2 87/4885HCAR3 2405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.